Bactobio

Bactobio is a London-based biotechnology company that employs cutting-edge technology to extract a wide range of chemicals from bacteria for medical and industrial applications. Leveraging synthetic biology, next-generation sequencing, and machine learning, Bactobio has developed the capability to culture the previously inaccessible 99% of microbes. This unique access to nature's abundant bioresources enables the company to unearth innovative chemical and biological products for the healthcare and agriculture sectors.

Founded in 2020, Bactobio's primary focus lies in the discovery of groundbreaking antibiotics to combat severe bacterial infections and contribute to the establishment of sustainable plant protection methods. The company recently secured a noteworthy £6.00M Convertible Note investment on 05 December 2022, with participation from prominent investors including Hugh Grant, Peder Nielsen, and the Bridford Group. This injection of funds is poised to further propel Bactobio's innovative research and development efforts, advancing its mission to redefine the boundaries of biotechnology and revolutionize the industries it operates within.